PCRX NASDAQ
Pacira BioSciences, Inc.
1W: +0.4%
1M: -5.2%
3M: -1.5%
YTD: +3.1%
1Y: -0.2%
3Y: -18.8%
5Y: -56.4%
$25.21
+0.20 (+0.80%)
Weekly Expected Move ±4.5%
$23
$24
$25
$26
$27
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-11-19
Earliest Filing
2025-04-07
Latest Filing
partner: 4
target: 2
acquirer: 1
Counterparties (Filed by PCRX)
7 relationshipsCompanies named in PCRX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Fresenius Kabi USA, LLC | — | partner | Counterparty in patent infringement settlement agreement involving license and payment | 2025-04-07 | View |
| eVenus Pharmaceutical Laboratories Inc. | — | partner | Counterparty in patent infringement settlement agreement involving license and payment | 2025-04-07 | View |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | — | partner | Counterparty in patent infringement settlement agreement involving license and payment | 2025-04-07 | View |
| Flexion Therapeutics, Inc. | — | target | Target company acquired by Pacira BioSciences, Inc. in a merger completed on November 19, 2021. | 2021-12-09 | View |
| Oyster Acquisition Company Inc. | — | acquirer | Wholly owned subsidiary of Pacira that entered into a Merger Agreement to acquire Flexion Therapeutics, Inc. | 2021-11-19 | View |
| Flexion Therapeutics, Inc. | — | target | Delaware corporation acquired by Oyster Acquisition Company Inc. in a merger transaction. | 2021-11-19 | View |
| American Stock Transfer & Trust Company, LLC | AIG | partner | Counterparty to the Contingent Value Right Agreement with Pacira BioSciences, Inc. | 2021-11-19 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-06-30 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-06-11 | Officer/Director Change; Shareholder Vote; Other Events; Exhibits | View | |
| 2026-04-30 | Earnings Release; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-28 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2026-01-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-10 | Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure; Financial Statements an | View | |
| 2025-07-07 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Creation of | Agreement | View |
| 2025-06-13 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-22 | Other Events | View | |
| 2025-04-07 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-03-14 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2025-02-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-30 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-01-21 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-01-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR